HUP0002742A3 - New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders - Google Patents

New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders

Info

Publication number
HUP0002742A3
HUP0002742A3 HU0002742A HUP0002742A HUP0002742A3 HU P0002742 A3 HUP0002742 A3 HU P0002742A3 HU 0002742 A HU0002742 A HU 0002742A HU P0002742 A HUP0002742 A HU P0002742A HU P0002742 A3 HUP0002742 A3 HU P0002742A3
Authority
HU
Hungary
Prior art keywords
mirtazapine
prophylaxis
treatment
new therapeutic
psychotic disorders
Prior art date
Application number
HU0002742A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of HUP0002742A2 publication Critical patent/HUP0002742A2/hu
Publication of HUP0002742A3 publication Critical patent/HUP0002742A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0002742A 1997-03-27 1998-03-25 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders HUP0002742A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97200881 1997-03-27
EP97202785 1997-09-11
PCT/EP1998/001920 WO1998043646A1 (en) 1997-03-27 1998-03-25 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders

Publications (2)

Publication Number Publication Date
HUP0002742A2 HUP0002742A2 (hu) 2001-05-28
HUP0002742A3 true HUP0002742A3 (en) 2003-03-28

Family

ID=26146283

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002742A HUP0002742A3 (en) 1997-03-27 1998-03-25 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders

Country Status (24)

Country Link
EP (1) EP0969845B1 (enExample)
JP (2) JP4377456B2 (enExample)
KR (1) KR100577865B1 (enExample)
CN (1) CN1226036C (enExample)
AR (1) AR012193A1 (enExample)
AT (1) ATE318604T1 (enExample)
AU (1) AU726194B2 (enExample)
BR (1) BR9808077A (enExample)
CA (1) CA2284551C (enExample)
CZ (1) CZ298105B6 (enExample)
DE (1) DE69833645T2 (enExample)
DK (1) DK0969845T3 (enExample)
ES (1) ES2259207T3 (enExample)
HU (1) HUP0002742A3 (enExample)
ID (1) ID22283A (enExample)
IL (1) IL123716A (enExample)
NO (1) NO994673L (enExample)
NZ (1) NZ337618A (enExample)
PL (1) PL191449B1 (enExample)
PT (1) PT969845E (enExample)
RU (1) RU2222330C2 (enExample)
TR (1) TR199902334T2 (enExample)
TW (1) TW587938B (enExample)
WO (1) WO1998043646A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
FR2797399B1 (fr) * 1999-08-13 2002-10-18 Aventis Pharma Sa Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
US6350773B1 (en) 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
JP2004518699A (ja) 2001-02-06 2004-06-24 アストラゼネカ・アクチエボラーグ クエチアピンを用いた物質乱用の治療方法
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
RU2232574C2 (ru) * 2002-04-05 2004-07-20 Новосибирский институт органической химии им. Н.Н.Ворожцова СО РАН Лекарственное средство для лечения различных форм депрессий "флуоглизин"
US20050095292A1 (en) 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
DK1541197T3 (da) * 2003-12-02 2009-06-15 Pharmaneuroboost N V Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1547650A1 (en) * 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN1968706A (zh) 2004-06-03 2007-05-23 霍夫曼-拉罗奇有限公司 用顺铂和egfr－抑制剂治疗
JP5001271B2 (ja) * 2006-06-09 2012-08-15 大日本住友製薬株式会社 新規テープ製剤
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
DE102012011839B4 (de) * 2012-06-14 2018-03-22 Norbert Müller Verwendung von Interferon-gamma in einem Verfahren zur Behandlung von psychiatrischen Erkrankungen
RU2509560C1 (ru) * 2013-03-22 2014-03-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые терапевтические комбинации миртазапина для применения при болевых расстройствах

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2410821A1 (de) * 1974-03-07 1975-09-18 Hoechst Ag Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine
EP0431663B1 (en) * 1989-12-06 1994-01-12 Akzo Nobel N.V. Stabilized solutions of psychotropic agents
FI111367B (fi) * 1991-02-04 2003-07-15 Aventis Pharma Inc Menetelmä terapeuttisesti käyttökelpoisten N-(aryylioksialkyyli)heteroaryyli-8-atsabisyklo[3.2.1]oktaanijohdannaisten valmistamiseksi ja menetelmässä käytetyt välituotteet
ZA935078B (en) * 1992-07-15 1994-02-07 Nicolaas Johannes Jaco Loetter Pharmaceutical composition
RU2062114C1 (ru) * 1992-09-30 1996-06-20 Московский научно-исследовательский институт психиатрии МЗ РФ Способ лечения эндогенных психозов
PT669128E (pt) * 1992-11-17 2000-06-30 Yoshitomi Pharmaceutical Micro-esfera de libertacao sustentada contendo antipsicoticos e processo para produzir a mesma
JPH07242669A (ja) * 1994-03-07 1995-09-19 Akikazu Ogawa 四環系とブチロフェノン誘導体を化学結合した化合物

Also Published As

Publication number Publication date
KR20010005677A (ko) 2001-01-15
HUP0002742A2 (hu) 2001-05-28
ID22283A (id) 1999-09-30
IL123716A0 (en) 1998-12-06
NZ337618A (en) 2000-06-23
AR012193A1 (es) 2000-09-27
NO994673D0 (no) 1999-09-24
PT969845E (pt) 2006-05-31
PL335890A1 (en) 2000-05-22
RU2222330C2 (ru) 2004-01-27
CZ298105B6 (cs) 2007-06-27
CA2284551C (en) 2007-06-12
CA2284551A1 (en) 1998-10-08
BR9808077A (pt) 2000-03-08
CN1251526A (zh) 2000-04-26
KR100577865B1 (ko) 2006-05-10
TW587938B (en) 2004-05-21
EP0969845A1 (en) 2000-01-12
ES2259207T3 (es) 2006-09-16
EP0969845B1 (en) 2006-03-01
TR199902334T2 (xx) 2000-01-21
DE69833645T2 (de) 2006-08-24
NO994673L (no) 1999-11-17
JP2009280596A (ja) 2009-12-03
IL123716A (en) 2001-03-19
AU7213998A (en) 1998-10-22
DK0969845T3 (da) 2006-06-19
PL191449B1 (pl) 2006-05-31
CZ343199A3 (cs) 2000-04-12
WO1998043646A1 (en) 1998-10-08
ATE318604T1 (de) 2006-03-15
DE69833645D1 (de) 2006-04-27
CN1226036C (zh) 2005-11-09
AU726194B2 (en) 2000-11-02
JP4377456B2 (ja) 2009-12-02
JP5023315B2 (ja) 2012-09-12
HK1023293A1 (en) 2000-09-08
JP2001521497A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
HUP0002742A3 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
HUP0200469A3 (en) Use of sulfamate derivatives for treating impulse control disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
IL139591A0 (en) Combination therapy for treatment of bipolar disorders
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
IL145301A0 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders
IL139592A0 (en) Combination therapy for treatment of refractory depression
IL127496A0 (en) The use of MMP inhibitors for the treatment of ocular angiogenesis
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
IL150290A0 (en) The use of mirtazapine for the treatment of sleep disorders
IL142589A0 (en) 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders
HUP9904030A3 (en) Use of tiagabine for production of pharmaceutical against psychotic disorders
IL140540A0 (en) Treatment of anxiety disorders
PT1698338E (pt) S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
HUP0200520A3 (en) Use of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia
IL143181A0 (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
GB9926985D0 (en) Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and-cyanamides for the treatment of diseases
SI1069900T1 (sl) Uporaba reboksetina za zdravljenje nevropsihiatricnih motenj
GB9923551D0 (en) Treatment of neuropsychiatric disorders
HK1055908A (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
GB9924942D0 (en) Treatment of movement disorders
GB9821610D0 (en) Treatment of neuropsychiatric disorders
GB2332626B (en) Medicaments for treatment of disorders of the middle ear
GB0029955D0 (en) Treatment of neuropsychiatric disorders

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: N.V. ORGANON, NL

Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished